Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21 - PubMed (original) (raw)
Clinical Trial
. 2000 May;6(5):1693-701.
Affiliations
- PMID: 10815887
Clinical Trial
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21
T Gilewski et al. Clin Cancer Res. 2000 May.
Abstract
Our objective was to determine whether an immune response can be generated against MUC1 peptide and against tumor cell MUC1 after vaccination with MUC1-keyhole limpet hemocyanin (KLH) conjugate plus QS-21 in breast cancer patients. Nine patients with a history of breast cancer but without evidence of disease were treated with MUC1-KLH conjugate plus QS-21, containing 100 microg of MUC1 and 100 microg of QS-21. s.c. vaccinations were administered at weeks 1, 2, 3, 7, and 19. Peripheral blood was drawn at frequent intervals to assess antibody titers. Skin tests were placed at weeks 1, 3, 9, and 21 to determine delayed type hypersensitivity reactions. Common toxicities included a local skin reaction at the site of the vaccine, usually of 4-5 days' duration, and mild flu-like symptoms usually of 1-2 days' duration. High IgM and IgG antibody titers against synthetic MUC1 were detected. IgG antibody titers remain elevated from a minimum of 106-137 weeks after the first vaccination. Binding of IgM antibody to MCF-7 tumor cells was observed in seven patients, although there was minimal binding of IgG antibody. Two patients developed significant antibody titers post-high-dose chemotherapy and stem cell reinfusion. There was no evidence of T cell activation. This MUC1-KLH conjugate plus QS-21 was immunogenic and well tolerated in breast cancer patients. Additional trials are ongoing to determine the optimal MUC1 peptide for use in larger clinical trials. Further investigation of vaccine therapy in high-risk breast cancer is warranted.
Similar articles
- Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, Houghton AN, Livingston PO. Gilewski TA, et al. Clin Cancer Res. 2007 May 15;13(10):2977-85. doi: 10.1158/1078-0432.CCR-06-2189. Clin Cancer Res. 2007. PMID: 17504999 Clinical Trial. - Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO. Sabbatini PJ, et al. Clin Cancer Res. 2007 Jul 15;13(14):4170-7. doi: 10.1158/1078-0432.CCR-06-2949. Clin Cancer Res. 2007. PMID: 17634545 - Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Ragupathi G, et al. Clin Cancer Res. 2003 Nov 1;9(14):5214-20. Clin Cancer Res. 2003. PMID: 14614001 - Ganglioside vaccines with emphasis on GM2.
Livingston P. Livingston P. Semin Oncol. 1998 Dec;25(6):636-45. Semin Oncol. 1998. PMID: 9865678 Review. - Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT, Kao CJ, Wolf M, DeGregorio MW. Wurz GT, et al. Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836. Hum Vaccin Immunother. 2014. PMID: 25483673 Free PMC article. Review.
Cited by
- Novel adjuvants in allergen-specific immunotherapy: where do we stand?
Lin YJ, Zimmermann J, Schülke S. Lin YJ, et al. Front Immunol. 2024 Feb 23;15:1348305. doi: 10.3389/fimmu.2024.1348305. eCollection 2024. Front Immunol. 2024. PMID: 38464539 Free PMC article. Review. - Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen.
Pifferi C, Aguinagalde L, Ruiz-de-Angulo A, Sacristán N, Baschirotto PT, Poveda A, Jiménez-Barbero J, Anguita J, Fernández-Tejada A. Pifferi C, et al. Chem Sci. 2023 Mar 1;14(13):3501-3513. doi: 10.1039/d2sc05639a. eCollection 2023 Mar 29. Chem Sci. 2023. PMID: 37006677 Free PMC article. - Research advance of natural products in tumor immunotherapy.
Huo JL, Fu WJ, Liu ZH, Lu N, Jia XQ, Liu ZS. Huo JL, et al. Front Immunol. 2022 Sep 2;13:972345. doi: 10.3389/fimmu.2022.972345. eCollection 2022. Front Immunol. 2022. PMID: 36159787 Free PMC article. Review. - MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization.
Son HY, Jeong HK, Apostolopoulos V, Kim CW. Son HY, et al. Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221112358. doi: 10.1177/03946320221112358. Int J Immunopathol Pharmacol. 2022. PMID: 35839304 Free PMC article. - Emerging role of natural products in cancer immunotherapy.
Dong S, Guo X, Han F, He Z, Wang Y. Dong S, et al. Acta Pharm Sin B. 2022 Mar;12(3):1163-1185. doi: 10.1016/j.apsb.2021.08.020. Epub 2021 Aug 21. Acta Pharm Sin B. 2022. PMID: 35530162 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous